Results 71 to 80 of about 663,256 (217)

A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment [PDF]

, 2008
Anthony Gonçalvès, Séverine Esteyriès, Brynn Taylor-Smedra, Arnaud Lagarde, Mounay Ayadi, Geneviève Monges, François Bertucci, Benjamin Esterni, Jean‐Robert Delpéro, Olivıer Turrini, Bernard Lelong, Patrice Viens, Jean‐Paul Borg, Daniel Birnbaum, Sylviane Olschwang, F. Viret   +15 more
openalex   +1 more source

SO-4 Progression-free survival in patients with cholangiocarcinoma with FGFR2 fusions or rearrangements: A FIGHT-202 post-hoc analysis of prior systemic therapy response [PDF]

, 2021
Ghassan K. Abou‐Alfa, Vaibhav Sahai, Antoine Hollebecque, Gina M. Vaccaro, Davide Melisi, Raed Moh’d Taiseer Al-Rajabi, Andrew Scott Paulson, Mitesh J. Borad, David Gallinson, Adrian Murphy, Do‐Youn Oh, Efrat Dotan, Daniel V.T. Catenacci, Eric Van Cutsem, Christine Lihou, H. Ren, Kristen Bibeau, Luis Féliz, Arndt Vogel   +18 more
openalex   +1 more source

383P Pre-treatment body mass index and neutrophil lymphocyte ratio predict 3-years progression free survival in locally advanced stage nasopharyngeal carcinoma [PDF]

, 2023
Ni Putu Merlynda Pusvita Dewi, Andhika Rachman, Cosphiadi Irawan   +2 more
openalex   +1 more source

Minimal Residual Disease after Conventional Treatment Significantly Impacts on Progression-Free Survival of Patients with Follicular Lymphoma: The FIL FOLL05 Trial [PDF]

, 2014
Sara Galimberti, Stefano Luminari, Elena Ciabatti, Susanna Grassi, Francesca Guerrini, Alessandra Dondi, Luigi Marcheselli, Marco Ladetto, Pier Paolo Piccaluga, Anna Gazzola, Claudia Mannu, Luigia Monitillo, Barbara Mantoan, Ilaria Del Giudice, Irene Della Starza, Marzia Cavalli, Luca Arcaini, Alessandra Tucci, Giuseppe A. Palumbo, Luigi Rigacci, Alessandro Pulsoni, Umberto Vitolo, Carola Boccomini, Daniele Vallisa, Giovanni Bertoldero, Gianluca Gaïdano, Pellegrino Musto, Mario Petrini, Massimo Federico   +28 more
openalex   +1 more source

Extended Survival and Prognostic Factors in Endometrial Cancer: A Multivariate Cox Regression Analysis

Clinical and Experimental Obstetrics & Gynecology
Background: Endometrial cancer (EC) is the third most prevalent neoplasm among women in Spain and the most frequent malignancy of the female genital tract. The primary risk factors are associated with increased estrogen levels.
Irene Valencia Téllez, Laura De Pablo Zamora, María Castillo Lara, Claudia Vivas Flores, Carlos Vega Reina, Juan Jesús Fernández Alba   +5 more
doaj   +1 more source

Progression-Free Survival of a Patient with Advanced Hepatocellular Carcinoma Treated with Adoptive Cell Therapy Using Natural Killer Cells: A Case Report

, 2022
Guodai Hong, Silun Xie, Zikuan Guo, Diping Zhang, Sihai Ge, Suqin Zhang, Wenbin Gao   +6 more
openalex   +2 more sources

Clinicopathologic significance of heat shock protein 60 as a survival predictor in breast carcinoma

Frontiers in Oncology
BackgroundWhile Heat Shock Protein 60 (HSP60) has been linked to human tumor, its clinic significance specifically in breast carcinoma is unclear. This investigation aims to retrospectively evaluate how HSP60 protein levels relate to survival outcomes ...
Qing Wang, Shengzhou Chen, Zhihong Wu, Jungang Ni   +3 more
doaj   +1 more source

P53 Mutations in Advanced Cancers: Clinical Characteristics, Outcomes, and Correlation between Progression-Free Survival and Bevacizumab-Containing Therapy [PDF]

, 2013
Rabih Said, David S. Hong, Carla L. Warneke, J. Jack Lee, Jennifer J. Wheler, Filip Jankú, Aung Naing, Gerald S. Falchook, Siqing Fu, Sarina A. Piha‐Paul, Apostolia M. Tsimberidou, Razelle Kurzrock   +11 more
openalex   +1 more source

Supplementary Material S3 from How to Deal with Interval-Censored Data Practically while Assessing the Progression-Free Survival: A Step-by-Step Guide Using SAS and R Software

, 2023
Audrey Emmanuelle Dugué, Marina Pulido, Sylvie Chabaud, Lisa Belin, Jocelyn Gal   +4 more
openalex   +1 more source

Predicting the survival probability of functional neuroendocrine tumors treated with peptide receptor radionuclide therapy: Serbian experience

Frontiers in Endocrinology
IntroductionPeptide receptor radionuclide therapy (PRRT) is a treatment option for well-differentiated, somatostatin receptor positive, unresectable or/and metastatic neuroendocrine tumors (NETs).
Vladimir Vukomanovic, Vladimir Vukomanovic, Katarina Vuleta Nedic, Katarina Vuleta Nedic, Marija Zivkovic Radojevic, Marija Zivkovic Radojevic, Aleksandar Dagovic, Aleksandar Dagovic, Neda Milosavljevic, Neda Milosavljevic, Marina Markovic, Marina Markovic, Vladimir Ignjatovic, Vladimir Ignjatovic, Ivana Simic Vukomanovic, Ivana Simic Vukomanovic, Svetlana Djukic, Svetlana Djukic, Marijana Sreckovic, Milena Backovic, Marko Vuleta, Aleksandar Djukic, Aleksandar Djukic, Verica Vukicevic, Vesna Ignjatovic, Vesna Ignjatovic   +25 more
doaj   +1 more source